Tag Archives: prior art

Method of Treatment Efficacy Benchmarks Avoid Inherency Attack

Posted on February 6, 2020 by Warren Woessner

In Galderma Labs. v. Teva Pharm. USA, Inc., Appeal Nos. 2019-2396 and 2020-1213 (Fed. Cir,. January 29, 2020), a Fed. Cir. panel of Judges Moore, O’Malley and Stoll reversed a district court finding that three Galderma patents (US Pat. Nos. … Continue reading →

Posted in Anticipation, Inherency | Tagged Federal Circuit, prior art | Leave a comment

Hulu v. Soundview Innovations – the Shifting Sands of Printed Publications

Posted on January 10, 2020 by Warren Woessner

In Hulu v Soundview Innovations, IPR2018-01039, the PTAB was faced with the question of whether or not a certain textbook was a “printed publication” that was “publicly available” and so qualified as prior art against U.S. Pat. No. 5,806,062 – … Continue reading →

Posted in 102 Patentability, Prior Art | Tagged IPR, prior art, PTAB | Leave a comment

Nuvo Pharms. v. Dr. Reddy’s Labs. – Catch 22 at the Federal Circuit?

Posted on November 21, 2019 by Warren Woessner

A “catch 22” is defined as a “dilemma or difficult circumstance from which there is no escape because of mutually conflicting or dependent conditions.” (As in if a pilot claims he is too mentally ill to fly missions, he has … Continue reading →

Posted in Federal Circuit, Prior Art | Tagged Federal Circuit, prior art | Leave a comment

Novartis v. West-Ward – Lead Compound Analysis v. Motivation to Combine

Posted on May 20, 2019 by Warren Woessner

In Novartis Pharm. v. West-Ward Pharm., Appeal no. 2018-1434 (Fed. Cir., May 12, 2019), a three judge panel of Stoll, Plager and Clevenger affirmed the district court’s ruling that the claims of Novartis’ U.S. Pat. No. 8,410,131, directed to using … Continue reading →